These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 11400148)

  • 1. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
    Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
    Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
    Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
    J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma.
    Tschugguel W; Pustelnik T; Lass H; Mildner M; Weninger W; Schneeberger C; Jansen B; Tschachler E; Waldhör T; Huber JC; Pehamberger H
    Br J Cancer; 1999 Mar; 79(9-10):1609-12. PubMed ID: 10188914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
    Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
    Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.
    Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C
    Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.
    Tu YT; Tao J; Liu YQ; Li Y; Huang CZ; Zhang XB; Lin Y
    Clin Exp Dermatol; 2006 May; 31(3):413-8. PubMed ID: 16681591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
    Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
    Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
    Kuźbicki L; Sarnecka A; Chwirot BW
    Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
    Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
    J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
    De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
    Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
    Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
    Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
    Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
    Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
    Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
    Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.